GlassScriptPhysician profile
Norys Castro Pena
NPI 1265797690
$5,780.26
in general payments reported to CMS, 2019-2025
27 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $238 · 2021: $486 · 2022: $1,005 · 2023: $1,248 · 2024: $1,126 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,428 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,427.69 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.06 | 2019-2025 | Mavyret, Ubrelvy |
| Viiv Healthcare Company | $1,260.68 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $712.17 | 2019-2025 | Biktarvy |
| Novo Nordisk INC | $359.85 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $359.85 | 2021-2025 | Capvaxive, Pneumovax 23, Vaxneuvance |
| Astellas Pharma US INC | $277.20 | 2019-2025 | Veozah |
| Dynavax Technologies Corporation | $153.35 | 2022-2024 | Heplisav-B |
| Insmed, INC. | $145.69 | 2022-2023 | Arikayce |
| Pfizer INC. | $140.63 | 2019-2025 | |
| Genentech USA, INC. | $138.88 | 2019-2024 | Lunsumio, Polivy |
| Sumitomo Pharma America, INC. | $115.34 | 2023-2024 | Gemtesa |
| Incyte Corporation | $103.05 | 2022 | |
| Amgen INC. | $100.77 | 2019-2024 | Repatha, Otezla |
| Melinta Therapeutics, LLC | $84.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $77.49 | 2024 | Calquence |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.58 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $46.11 | 2025 | Rexulti |
| Galderma Laboratories, L.P. | $34.81 | 2023 | |
| Sunovion Pharmaceuticals INC. | $28.91 | 2022 | |
| Madrigal Pharmaceuticals | $21.31 | 2024 | Resmetirom |
| Cipher Pharmaceuticals US LLC | $20.70 | 2025 | Natroba, Spinosad |
| Janssen Biotech, INC. | $18.82 | 2023 | Symtuza |
| Lilly USA, LLC | $18.14 | 2023 | Mounjaro |
| Paratek Pharmaceuticals, INC. | $15.53 | 2023 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.86 | 2023 | Xifaxan |
| Radius Health, INC. | $12.71 | 2019 | |
| Amarin Pharma, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norys Castro Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.